Venetoclax - a novel, orally bioavailable inhibitor of B-cell lymphoma-2 - has demonstrated substantial clinical activity in the treatment of chronic lymphocytic leukemia. Alone or in combination with other targeted agents, venetoclax results in high rate of d... ...

请注册登录后继续浏览